INTRODUCTION
Many inflammatory conditions are severe, chronic, and disabling diseases that can manifest in joints and skin. Rheumatoid arthritis (RA), which affects approximately 1.5 million adults in the US and an estimated 0.5-1% of people in developed nations, primarily affects the synovial membrane in the joints [1] . Psoriasis (PsO) is a skin disease occurring in approximately 4.5 million adults in the US, with an estimated prevalence of 1.4-2.5% in children, adolescents, and adults in the US [2] . PsO is frequently accompanied by comorbid psoriatic arthritis (PsA), a disfiguring form of arthritis with an estimated prevalence of 11% in patients with PsO in the US [3] . Ankylosing spondylitis (AS), with prevalence estimated to be 30-900 per 100,000 people in the US, is a type of arthritis that affects the spine [1] . In addition to symptoms associated with these diseases (pain and swelling of joints and plaque formation on skin), patients suffer impaired health-related quality of life [4, 5] .
Biologic therapies that target specific components of the immune system are important for treatment of autoimmune diseases. These include agents that target tumor necrosis factor (adalimumab, The cost of biologic therapies is high compared to non-biologic DMARDs;
evidence-based assessment of comparative costs between biologics is critical to ensure rational healthcare resource allocation. Data comparing costs across indications from the payer's perspective and an understanding of biologic dosing patterns across different populations and payers are critical for formulary decision-makers to develop evidence-based formularies. Although prior studies evaluated the comparative costs of biologics across multi-payer claims databases, the data used in those studies are now relatively outdated and such analyses of multi-payer data may be less applicable to specific payers. We now report the results from a biologic utilization model using more recent utilization data from claims for beneficiaries on a biologic enrolled in a health plan of a large national commercial health insurer.
METHODS

Data Source
Data for this study were obtained from the 
Statistical Considerations
Frequency and percentage were calculated for categorical patient characteristics and study outcomes, including treatment patterns.
Analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). The mean annual costs per treated patient were estimated by dividing the calculated total cost incurred by all patients treated with the biologic at index within each disease subcohort. No adjusted analyses were conducted, as the findings were meant to provide population-wide estimates for eligible patients included in this database. Propensity score weighting was not implemented.
RESULTS
Patients
A total of 59,436 patients were treated with an eligible biologic during the identification period and of these, 20,159 met all of the inclusion/ exclusion criteria (Fig. 1) . The most commonly used index medications were etanercept (45%), adalimumab (32%), and infliximab (9%; Table 1 ). The most common indications were RA only (47%), PsO only (25%), and PsA only (9%). The mean age of the population was 47.6 years; mean age was \45 years for patients (n range = 165-9116) ( Table 2) . Among patients diagnosed with PsO only, those Demographic and clinical characteristics are not presented for patients treated with tofacitinib because of small sample size (n =
5)
ABA abatacept, ADA adalimumab, CER certolizumab pegol,
UST ustekinumab Table 2 Mean annual total cost (US $) per treated patient 
Treatment Patterns
Across all patients, persistence was greatest among patients treated with infliximab (66-79%) compared to 41-59% for all other medications except golimumab and tofacitinib (Table 3) . Patients treated with golimumab had persistence rates of 11-25% due in large part to higher rates of switching (50-76%). Persistence rates were generally 15-25% higher among patients continuing on their index therapy compared to those who were new to therapy.
DISCUSSION
This was a retrospective analysis of total annual cost of biologic treatment and biologic utilization among patients diagnosed with at least one of four autoimmune conditions: RA, PsO, PsA, or AS. The most commonly used medications were etanercept, adalimumab, and infliximab, which is consistent with previous findings [6] [7] [8] . Notably, the most common medications had been approved longer than the other biologics included in the study. While most of the patients were considered to be continuing on existing biologic therapies, a few medication cohorts (rituximab, certolizumab, and tofacitinib) were more often new users.
The findings of this study indicate that there is a large amount of variability in biologic cost both within and between condition cohorts, which may originate from small sample sizes in some cases. For example, among patients treated for RA, costs ranged from $18,769 for treatment with tofacitinib to $30,269 for adalimumab. Even after excluding the very small cohort of patients treated with tofacitinib (n = 5) and rituximab, which has a unique dosing schedule, results still ranged from $21,877 to $30,269, which represents a difference of 38%. The greatest variability was observed among patients treated for PsO only. Ustekinumab had the greatest cost ($53,746), which was 66% more than the cost of infliximab, 72% more than the cost of etanercept, and 84% more than the cost of adalimumab. Another factor that seems to be associated with increased cost is whether the patient is new to therapy at index, or continuing therapy from baseline to follow-up. Etanercept was the most commonly used medication in this study and in a prior study [9] . Similar to the prior study, newer biologics had equivalent or lower costs than etanercept for RA, PsA, and AS. The current study also confirms the observation that for biologics that are indicated for all four inflammatory diseases (etanercept, adalimumab, and infliximab), etanercept had the lowest annual acquisition and administration costs [9] .
This study has inherent limitations associated with observational studies based on administrative claims. Specifically, while claims data indicate whether a prescription was filled, they do not indicate if the medication was used as prescribed or at all. This study included only Table 3 continued Pattern, n 
